Ads
related to: breast cancer clinical trials names searchpfizerclinicaltrials.com has been visited by 10K+ users in the past month
breastcancernow.org has been visited by 10K+ users in the past month
Search results
Results from the WOW.Com Content Network
Buparlisib was under investigation as a treatment for advanced or metastatic HER2-negative breast cancer in several phase III clinical trials: . The phase III trial BELLE-2 compared buparlisib + fulvestrant with fulvestrant alone in patients with advanced or metastatic HER2-negative, hormone receptor-positive (HR+) aromatase inhibitor-resistant breast cancer.
2014: A phase 1 clinical trial of MK-2206 with a variety of other agents in 72 patients with advanced cancer reported acceptable side-effects. [3] 2016: MK-2206 is one of the treatments in the I-SPY2 Adaptive clinical trial for breast cancer that had been selected for later stage trials. [5]
Tucatinib, sold under the brand name Tukysa, is an anticancer medication used for the treatment of HER2-positive breast cancer. [3] [4] It is a small molecule inhibitor of HER2. [6] [7] It was developed by Array BioPharma and licensed to Cascadian Therapeutics (formerly Oncothyreon, subsequently part of Seattle Genetics). [8]
Palbociclib (PD-033299, trade name Ibrance) gave encouraging results in a phase II clinical trial on patients with HR-positive, HER2-negative advanced breast cancer. [14] The addition of PD-0332991 to letrozole trebled median time to disease progression to 26.1 months compared with 7.5 months for letrozole alone.
A number of early phase clinical trials of gedatolisib for treatment of endometrial cancer, colorectal cancer, acute myeloid leukemia have been conducted. [8] [9] [10] Current clinical trials are focused on breast cancer, [11] [12] [13] [14]
In pancreatic cancer. Dinaciclib inhibits pancreatic cancer growth and progression in murine xenograft models. [8] In osteosarcoma Dinacliclib induces the apoptosis of osteosarcoma cells. [9] Apoptosis of osteosarcoma cultures can be induced by the combination of the cyclin-dependent kinase inhibitor SCH727965 and a heat shock protein 90 ...
Approval was based on the EMILIA study, [15] a phase III clinical trial that compared trastuzumab emtansine versus capecitabine (Xeloda) plus lapatinib (Tykerb) in 991 people with unresectable, locally advanced or metastatic HER2-positive breast cancer who had previously been treated with trastuzumab and taxane chemotherapy. [15]
Abemaciclib, sold under the brand name Verzenio among others, is a medication for the treatment of advanced or metastatic breast cancers. It was developed by Eli Lilly and it acts as a CDK inhibitor selective for CDK4 and CDK6. [4] It was designated as a breakthrough therapy for breast cancer by the US Food and Drug Administration (FDA) in ...
Ads
related to: breast cancer clinical trials names searchpfizerclinicaltrials.com has been visited by 10K+ users in the past month
breastcancernow.org has been visited by 10K+ users in the past month